- On 13 August 2026, Zoetis Inc. announced that its Simparica Trio chewable received U.S. FDA Emergency Use Authorization to treat life-threatening New World screwworm infestations in dogs and puppies.
- This temporary authorization underscores Zoetis’s capacity to rapidly repurpose an established parasiticide franchise for emerging threats in the companion-animal market.
- We’ll now explore how this emergency expansion of Simparica Trio’s use could influence Zoetis’s broader investment narrative and growth drivers.
Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
Zoetis Investment Narrative Recap
To own Zoetis, you need to believe in long term demand for animal health products and the company’s ability to refresh key franchises like Simparica Trio, dermatology and osteoarthritis pain. The New World screwworm Emergency Use Authorization highlights Zoetis’s scientific depth, but it does not clearly change the most immediate catalyst, which remains a stabilization in U.S. companion animal trends after lowered 2026 guidance, or the key risk of mounting competition in core parasiticide and dermatology categories.
The most relevant recent announcement alongside the Simparica Trio EUA is Zoetis’s 8 August 2026 guidance cut, which reset expectations for 2026 revenue to US$9.12–US$9.32 billion and EPS to US$5.55–US$5.65. That revision framed how sensitive the story currently is to any sign of renewed growth in companion animal products. Against that backdrop, investors are likely to view the EUA as a helpful but temporary addition rather than a solution to the broader guidance reset.
Yet beneath Zoetis’s product wins, investors should also be aware of intensifying competition and pricing pressure risk...
Read the full narrative on Zoetis (it's free!)
Zoetis' narrative projects $10.7 billion revenue and $3.1 billion earnings by 2029. This requires 3.9% yearly revenue growth and a $0.4 billion earnings increase from $2.7 billion today.
Uncover how Zoetis' forecasts yield a $114.76 fair value, a 48% upside to its current price.
Exploring Other Perspectives
Compared with the baseline, the most bearish analysts were assuming only about 3 percent annual revenue growth to roughly US$10.4 billion and earnings of about US$3.0 billion by 2029, so if you see Simparica Trio’s EUA as evidence of a more resilient innovation and margin story than that, you may find their much more cautious narrative worth testing against your own expectations.
Explore 11 other fair value estimates on Zoetis - why the stock might be worth just $80.00!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Zoetis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance.
Want Some Alternatives?
Our top stock finds are flying under the radar-for now. Get in early:
- Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com